Journal of Clinical Pediatrics >
Clinical efficacy and prognosis analysis of 60 high-risk neuroblastoma with children in a single center
Received date: 2023-06-06
Online published: 2024-10-08
Objective To analyze the clinical characteristics and prognosis factors of high-risk neuroblastoma (NB) in children. Methods A retrospective analysis of clinical data collected from children with high-risk NB from May 2017 to May 2022. Follow-up was conducted until February 1,2023. Prognosis-related factors were analyzed by comparing different clinical characteristics, treatment regimens, and survival status. Results Sixty high-risk NB children were included in this study, consisting of 36 males (60.0%) and 24 females (40.0%). The median age at diagnosis was 45 (8-103) months, median follow-up time was 39 (2-65) months, median time to disease progression/recurrence was 18 (2-62) months; and the median survival time was 41 months.. The 1-year, 2-year and 3-year overall survival (OS) rate were 76.4%, 65.6% and 54.8% respectively. The event-free survival (EFS) rate at 1 year, 2 years, and 3 years were 63.0%, 41.9% and 31.6% respectively. As of February 1, 2023, there were 34 survivors (56.7%) and 26 deaths (43.3%), with 17 of the deaths (65.3%) due to recurrence. Univariate survival analysis showed that pathological type, clinical stage,surgical status at initial diagnosis, bone marrow metastasis status, MYCN amplification, anemia status, NSE level, LDH level, and intracranial metastasis at relapse were adverse prognosis risk for high-risk NB (P<0.05). Cox multivariate analysis showed MYCN amplification, and bone marrow metastases at initial diagnosis were independent prognostic factors for high-risk NB (P=0.017). Conclusion The 3-year OS rate of high-risk NB children was 54.8%, High-risk neuroblastoma has a poor overall prognosis, with recurrence being the main cause of death. MYCN amplification is an independent adverse prognostic factor for high-risk NB.
Key words: neuroblastoma; high-risk; prognosis; risk factors
Wei TANG , Kailan CHEN , Yingming NIE , Bin WU , Sha WU , Zijian FANG , Hui LI . Clinical efficacy and prognosis analysis of 60 high-risk neuroblastoma with children in a single center[J]. Journal of Clinical Pediatrics, 2024 , 42(10) : 881 -887 . DOI: 10.12372/jcp.2024.23e0511
[1] | Qiu B, Matthay KK. Advancing therapy for neuroblastoma[J]. Nat Rev Clin Oncol, 2022, 19(8): 515-533. |
[2] | 中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科学分会肿瘤外科学组. 儿童神经母细胞瘤诊疗专家共识[J]. 中华小儿外科杂志, 2015, 36(1): 3-7. |
[3] | Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment[J]. J Clin Oncol, 1993, 11(8): 1466-1477. |
[4] | Maris JM. Recent advances in neuroblastoma[J]. N Engl J Med, 2010, 362(23): 2202-2211. |
[5] | Smith V, Foster J. High-risk neuroblastoma treatment review[J]. Children (Basel), 2018, 5(9): 114. |
[6] | Ladenstein R, P?tschger U, Pearson ADJ, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(4): 500-514. |
[7] | Elzembely MM, Dahlberg AE, Pinto N, et al. Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue[J]. Pediatr Blood Cancer, 2019, 66(1): e27421. |
[8] | 苏雁, 马晓莉, 王焕民, 等. 单中心458例高危神经母细胞瘤患儿临床特征及预后分析[J]. 中华儿科杂志, 2020, 58(10): 796-801. |
[9] | 王培培, 唐锁勤, 翟谦宇. 儿童Ⅲ/Ⅳ期神经母细胞瘤的综合治疗及生存分析[J]. 解放军医学院学报, 2019, 40(6): 533-536. |
[10] | Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage[J]. Science, 1984, 224(4653): 1121-1124. |
[11] | Floros KV, Cai J, Jacob S, et al. MYCN-amplified neuroblastoma is addicted to Iron and vulnerable to inhibition of the system Xc-/glutathione axis[J]. Cancer Res, 2021, 81(7): 1896-1908. |
[12] | Irwin MS, Naranjo A, Zhang FF et al. Revised neuroblastoma risk classification system: a report from the children's oncology group[J]. J Clin Oncol, 2021, 39(29): 3229-3241. |
[13] | MacFarland S, Bagatell R. Advances in neuroblastoma therapy[J]. Curr Opin Pediatr, 2019, 31(1): 14-20. |
[14] | Holmes K, P?tschger U, Pearson ADJ, et al. Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1/SIOPEN study[J]. J Clin Oncol, 2020, 38(25):2902-2915. |
[15] | Berthold F, Ernst A, Hero B, et al. Correction: long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation[J]. Br J Cancer, 2019, 121(10): 894-895. |
[16] | 张朝霞, 钟笛箫, 李君惠, 等. 自体造血干细胞移植治疗高危神经母细胞瘤临床分析[J]. 北京医学, 2020, 42(11): 5. |
[17] | Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial[J]. JAMA, 2019, 322(8): 746-755. |
[18] | Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334. |
[19] | Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial[J]. Lancet Oncol, 2017, 18(7):946-957. |
[20] | Mody R, Yu AL, Naranjo A, et al. Irinotecan, temozo-lomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the children's oncology group[J]. J Clin Oncol, 2020, 38(19): 2160-2169. |
[21] | Ladenstein R, P?tschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12): 1617-1629. |
/
〈 |
|
〉 |